Soliris Could Drive Myasthenia Gravis Treatment Market Value Beyond $550 Million by 2024
- Written by PitchEngine.com.au
The global market for myasthenia gravis therapeutics is anticipated to more than treble in value from $146.4 million in 2014 to $550.4 million by 2024, driven primarily by the potential entry of Alexion’s Soliris during the forecast period.
Reportstack’s latest report "OpportunityAnalyzer: Myasthenia Gravis-Opportunity Analysis and...
Read more: Soliris Could Drive Myasthenia Gravis Treatment Market Value Beyond $550 Million by 2024

